Pharmacological management of narcolepsy

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 10, 2003, Pages 1739-1746

  Lammers, Gert Jan ^a   Overeem, Sebastiaan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

hydroxybutyrate; Hypocretin; Modafinil; Narcolepsy; Orexin; Pregnancy; Therapy

Indexed keywords

4 HYDROXYBUTYRIC ACID; BROFAROMINE; CAFFEINE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; CODEINE; DEXAMPHETAMINE; EPHEDRINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LEVODOPA; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; OREXIN; OXYBATE SODIUM; PEMOLINE; PRAZOSIN; PROLINTANE; PROTRIPTYLINE; PSYCHOSTIMULANT AGENT; SELEGILINE; TRICYCLIC ANTIDEPRESSANT AGENT; TYROSINE; UNINDEXED DRUG; VENLAFAXINE;

BODY WEIGHT DISORDER; CATAPLEXY; CLINICAL FEATURE; CLINICAL TRIAL; COMA; CONSTIPATION; DRUG HALF LIFE; EJACULATION DISORDER; HEADACHE; HUMAN; HYPNAGOGIC HALLUCINATION; IMPOTENCE; IRRITABILITY; LIVER FAILURE; MITRAL VALVE REGURGITATION; NARCOLEPSY; NAUSEA; NERVOUSNESS; ORGASM DISORDER; PARASOMNIA; PENIS ERECTION; PREGNANCY; PULMONARY HYPERTENSION; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEAT GLAND DISEASE; TACHYCARDIA; URINE INCONTINENCE; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG THERAPY, COMBINATION; HUMANS; LIFE STYLE; NARCOLEPSY;

EID: 0142241295     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.10.1739     Document Type: Review

References (83)

1. OVEREEM S, MIGNOT E, VAN DIJK JG, LAMMERS GJ: Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J. Clin. Neurophysiol. (2001) 18(2):78-105.
2. DAHMEN N, BIERBRAUER J, KASTEN M: Increased prevalence of obesity in narcoleptic patients and relatives. Eur. Arch. Psychiatry Clin. Neurosci. (2001) 251(2):85-89.
3. BROUGHTON R, VALLEY V, AGUIRRE M, ROBERTS J, SUWALSKI W, DUNHAM W: Excessive daytime sleepiness and the pathophysiology of narcolepsy-cataplexy: a laboratory perspective. Sleep (1986) 9(1 Pt 2):205-215.
4. LIN L, FARACO J, LI R et al.: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell (1999) 98(3):365-376.
5. CHEMELLI RM, WILLIE JT, SINTON CM et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell (1999) 98(4):437-451.
6. NISHINO S, RIPLEY B, OVEREEM S, LAMMERS GJ, MIGNOT E: Hypocretin (orexin) deficiency in human narcolepsy. Lancet (2000) 355(9197):39-40.
7. MIGNOT E, LAMMERS GJ, RIPLEY B et al.: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. (2002) 59(10):1553-1562.
8. PEYRON C, FARACO J, ROGERS W et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. (2000) 6(9):991-997.
9. THANNICKAL TC, MOORE RY, NIENHUIS R et al.: Reduced number of hypocretin neurons in human narcolepsy. Neuron (2000) 27(3):469-474.
10. PEYRON C, TIGHE DK, DEN POL AN et al.: Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. (1998) 18(23):9996-10015.
11. NISHINO S, MIGNOT E: Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. (1997) 52(1):27-78.
12. MITLER MM, ERMAN M, HAJDUKOVIC R: The treatment of excessive somnolence with stimulant drugs. Sleep (1993) 16(3):203-206.
13. PARKES JD, DAHLITZ M: Amphetamine prescription. Sleep (1993) 16(3):201-203.
14. MULLINGTON J, BROUGHTON R: Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep (1993) 16(5):444-456.
15. ROEHRS T, ZORICK F, WITTIG R, PAXTON C, SICKLESTEEL J, ROTH T: Alerting effects of naps in patients with narcolepsy. Sleep (1986) 9(1 Pt 2):194-199.
16. ROGERS AE, ALDRICH MS: The effect of regularly scheduled naps on sleep attacks and excessive daytime sleepiness associated with narcolepsy. Nurs. Res. (1993) 42(2):111-117.
17. GODBOUT R, MONTPLAISIR J: The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin. Neuropharmacol. (1986) 9(1):46-51.
18. BRUCK D, ARMSTRONG S, COLEMAN G: Sleepiness after glucose in narcolepsy. J. Sleep Res. (1994) 3(3):171-179.
19. GARMA L, MARCHAND F: Non-pharmacological approaches to the treatment of narcolepsy. Sleep (1994) 17(8 Suppl.):S97-S102.
20. AMERICAN SLEEP DISORDERS ASSOCIATION: Practice parameters for the use of stimulants in the treatment of narcolepsy. Sleep (1994) 17:348-351.
21. MITLER MM, ALDRICH MS, KOOB GF, ZARCONE VP: Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep (1994) 17(4):352-371.
22. MITLER MM, HAJDUKOVIC R: Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep (1991) 14(3):218-220.
23. ZWICKER J, BRUCK D, PARKES JD, BROUGHTON RJ: Acute mood improvement after dextroamphetamine and methylphenidate in narcolepsy. J. Sleep Res. (1995) 4(4):252-255.
24. MITLER MM: Evaluation of treatment with stimulants in narcolepsy. Sleep (1994) 17(8 Suppl.):S103-S106.
25. WALLIN MT, MAHOWALD MW: Blood pressure effects of long-term stimulant use in disorders of hypersomnolence. J. Sleep Res. (1998) 7(3):209-215.
26. RICH S, RUBIN I, WALKER AM, SCHNEEWEISS S, ABENHAIM L: Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest (2000) 117(3):870-874.
27. RYAN DH, BRAY GA, HELMCKE F et al.: Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes. Res. (1999) 7(4):313-322.
28. SCAMMELL TE, ESTABROOKE IV, MCCARTHY MT et al.: Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J. Neurosci. (2000) 20(22):8620-8628.
29. BROUGHTON RJ, FLEMING JA, GEORGE CF et al.: Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology (1997) 49(2):444-451.
30. US MODAFINIL MULTICENTER STUDY GROUP: Randomized trial of modafinil as a treament for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology (2000) 54(5):1166-1175.
31. US MODAFINIL MULTICENTER STUDY GROUP: Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann. Neurol. (1998) 43:88-97.
32. LAFFONT F, MAYER G, MINZ M: Modafinil in diurnal sleepiness. A study of 123 patients. Sleep (1994) 17(8 Suppl.):S113-S115.
33. BILLIARD M, BESSET A, MONTPLAISIR J et al.: Modafinil: a double-blind multicentric study. Sleep (1994) 17(8 Suppl.):S107-S112.
34. FRY JM: Treatment modalities for narcolepsy. Neurology (1998) 50(2 Suppl. 1):S43-S48.
35. BASTUJI H, JOUVET M: Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog. Neuropsychopharmacol. Biol. Psychiatry (1988) 12(5):695-700.
36. ROBERTSON P, DECORY HH, MADAN A, PARKINSON A: In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab. Dispos. (2000) 28(6):664-671.
37. HELLRIEGEL ET, ARORA S, NELSON M, ROBERTSON P Jr: Steady-state pharmacokinetics and tolerability of modafinil given alone or in combination with methylphenidate in healthy volunteers. J. Clin. Pharmacol. (2001) 41(8):895-904.
38. HUBLIN C, PARTINEN M, HEINONEN EH, PUUKKA P, SALMI T: Selegiline in the treatment of narcolepsy. Neurology (1994) 44(11):2095-2101.
39. HOHAGEN F, MAYER G, MENCHE A et al.: Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine-a pilot study. J. Sleep Res. (1993) 2(4):250-256.
40. BOIVIN DB, MONTPLAISIR J: The effects of L-dopa on excessive daytime sleepiness in narcolepsy. Neurology (1991) 41(8):1267-1269.
41. FRY JM, PRESSMAN MR, DIPHILLIPO MA, FORST-PAULUS M: Treatment of narcolepsy with codeine. Sleep (1986) 9(1 Pt 2):269-274.
42. SCRIMA L, HARTMAN PG, JOHNSON FH Jr, HILLER FC: Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy- cataplexy: double-blind subjective measures. Biol. Psychiatry (1989) 26(4):331-343.
43. LAMMERS GJ, ARENDS J, DECLERCK AC, FERRARI MD, SCHOUWINK G, TROOST J: Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep (1993) 16(3):216-220.
44. BROUGHTON R, MAMELAK M: Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can. J. Neurol. Sci. (1980) 7(1):23-31.
45. HUBLIN C: Narcolepsy: current drug treatment options. CNS Drugs (1996) 5(6):426-436.
46. DANIELS LE: Narcolepsy. Medicine (1934) 13(1):1-122.
47. MOURET J, LEMOINE P, SANCHEZ P, ROBELIN N, TAILLARD J, CANINI F: Treatment of narcolepsy with L-tyrosine. Lancet (1988) 2(8626-8627):1458-1459.
48. ELWES RD, CREWES H, CHESTERMAN LP et al.: Treatment of narcolepsy with L-tyrosine: double-blind placebo- controlled trial. Lancet (1989) 2(8671):1067-1069.
49. HENRY GK, HART RP, KWENTUS JA, SICOLA MJ: Effects of protriptyline on vigilance and information processing in narcolepsy. Psychopharmacology (Berl.) (1988) 95(1):109-112.
50. MITLER MM, SHAFOR R, HAJDUKOVICH R, TIMMS RM, BROWMAN CP: Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep (1986) 9(1 Pt 2):260-264.
51. GUILLEMINAULT C: Cataplexy. In: Narcolepsy. Guilleminault C, Dement WC, Passouant P (Eds), Spectrum, New York, USA (1976):125-144.
52. HISHIKAWA Y, IDA H, NAKAI K, KANEKO Z: Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). J. Neurol. Sci. (1966) 3(5):453-461.
53. MOURTAZAEV M. Clinical and physiological analysis and treatment of narcolepsy and idiopathic hypersomnia. Moscow (1982) (Thesis).
54. PARKES D: Introduction to the mechanism of action of different treatments of narcolepsy. Sleep (1994) 17(8 Suppl.):S93-S96.
55. SCHACHTER M, PARKES JD: Fluvoxamine and domipramine in the treatment of cataplexy. J. Neurol. Neurosurg. Psychiatry (1980) 43(2):171-174.
56. LANGDON N, LOCK C, WELSH K et al.: Immune factors in narcolepsy. Sleep (1986) 9(1 Pt 2):143-148.
57. SCHRADER H, KAYED F, BENDIXEN MARKSET AC, TREIDENE HE: The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol. Scand. (1986) 74(4):297-303.
58. NISHINO S, ARRIGONI J, SHELTON J, DEMENT WC, MIGNOT E: Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep (1993) 16(8):706-712.
59. PASSOUANT P, RALDY-MOULINIER M, AUSSILLOUX C: [Cataplexy associated with Gelineau's disease; effect of clomipramine]. Rev. Neurol. (Paris) (1970) 123(1):56-60.
60. PARKES JD: Sleep and its disorders. WB Saunders Company, London, UK (1985).
61. HISHIKAWA Y, SHIMIZU T: Physiology of REM sleep, cataplexy, and sleep paralysis. Adv. Neurol. (1995) 67:245-271.
62. MAMELAK M, SCHARF MB, WOODS M: Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep (1986) 9(1 Pt 2):285-289.
63. US XYREM MULTICENTER STUDY GROUP: A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep (2002) 25(1):42-49.
64. US XYREM MULTICENTER STUDY GROUP: A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep (2003) 26(1):31-35.
65. ZVOSEC DL, SMITH SW, MCCUTCHEON JR, SPILLANE J, HALL BJ, PEACOCK EA: Adverse events, including death, associated with the use of 1,4-butanediol. N. Engl. J. Med. (2001) 344(2):87-94.
66. PARKES JD, SCHACHTER M: Mazindol in the treatment of narcolepsy. Acta Neurol. Scand. (1979) 60(4):250-254.
67. IIJIMA S, SUGITA Y, TESHIMA Y, HISHIKAWA Y: Therapeutic effects of mazindol on narcolepsy. Sleep (1986) 9(1 Pt 2):265-268.
68. HUBLIN C, LAUNES J, NIKKINEN P, PARTINEN M: Dopamine D2-receptors in human narcolepsy: a SPECT study with 123I-IBZM. Acta Neurol. Scand. (1994) 90(3):186-189.
69. GUILLEMINAULT C, MIGNOT E, ALDRICH M, QUERA-SALVA MA, TIBERGE M, PARTINEN M: Prazosin contraindicated in patients with narcolepsy. Lancet (1988) 2(8609):511.
70. ALDRICH MS, ROGERS AE: Exacerbation of human cataplexy by prazosin. Sleep (1989) 12(3):254-256.
71. SCHARF MB, BROWN D, WOODS M, BROWN L, HIRSCHOWITZ J: The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J. Clin. Psychiatry (1985) 46(6):222-225.
72. SCRIMA L, HARTMAN PG, JOHNSON FH Jr, THOMAS EE, HILLER FC: The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep (1990) 13(6):479-490.
73. THORPY MJ, SNYDER M, ALOE FS, LEDEREICH PS, STARZ KE: Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep (1992) 15(3):212-216.
74. BROUGHTON R, DUNHAM W, WEISSKOPF M, RIVERS M: Night sleep does not predict day sleep in narcolepsy. Electroencephalogr. Clin. Neurophysiol. (1994) 91(1):67-70.
75. LAMMERS GJ, ARENDS J, DECLERCK AC, KAMPHUISEN HA, SCHOLTWINK G, TROOST J: Ritanserin, a 5-HT2 receptor blocker, as add-on treatment in narcolepsy. Sleep (1991) 14(2):130-132.
76. GUILLEMINAULT C: Amphetamines and narcolepsy: use of the Stanford database. Sleep (1993) 16(3):199-201.
77. NISHINO S, ARRIGONI J, SHELTON J, KANBAYASHI T, DEMENT WC, MIGNOT E: Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J. Neurosci. (1997) 17(16):6401-6408.
78. BRIGGS GG, FREEMAN K, YAFFE SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Lipponcott Williams and Wilkins, Philadelphia, USA (2002).
79. ALTSHULER LL, SZUBA MD: Course of psychiatric disorders in pregnancy Dilemmas in pharmacologic management. Neurol. Clin. (1994) 12:613-635.
80. BRUNEL P, VIAL T, ROCHE I, BERTOLOTTI E, EVREUX JC: Follow-up of 151 pregnant women exposed to antidepressant treatment (MAOI excluded) during organogenesis Therapie (1994) 49:117-122.
81. BLOEM BR, LAMMERS GJ, ROOFTHOOFT DW, DE BEAUFORT AJ, BROUWER OF: Clomipramine withdrawal in newborns. Arch. Dis. Child Fetal Neonatal Ed. (1999) 81(1):F77.
82. PASTUSZAKA, SCHICK-BOSCHETTO B, ZUBER B et al.: Pregnancy outcome following first-trimester exposure to fluoxetine. JAMA (1993) 269:2246-2248.
83. KULIN NA, PASTUSZAK A, SAGE SR et al.: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA (1998) 279:609-610.